A method for simultaneously determining the contents of three residual solvents in piperaquine phosphate

Through gas chromatography and headspace sampling technology, the problem that the existing technology cannot determine the three residual solvents in piperiquine phosphate is solved, and the simultaneous detection of methanol, ethanol and 1-bromo-3-chloropropane is achieved, which improves the Accuracy and safety of drug quality control.

CN115575544BActive Publication Date: 2024-11-15GUANGXI ZHUANG AUTONOMOUS REGION DRUG INSPECTION INSTITUTE (GUANGXI ZHUANG AUTONOMOUS REGION DRUG PACKAGING MATERIAL CONTAINER PRODUCT TESTING CENTER GUANGXI ASEAN DRUG MEDICAL DEVICE INSPECTION INSTITUTE) +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202211306615.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-10-25
Publication Date
2024-11-15
Estimated Expiration
2042-10-25

AI Technical Summary

Technical Problem

The existing methods cannot effectively determine the content of the three residual solvents methanol, ethanol and 1-bromo-3-chloropropane in piperiquine phosphate, resulting in the lack of drug quality control and poses safety hazards.

Method used

Using gas chromatography combined with headspace sampling technology, gas chromatography is performed by mixing pipenoquine phosphate, ethylene glycol and sulfuric acid to be tested, and the content of three residual solvents is calculated by using the external standard method to ensure the accuracy of the measurement results and improve the accuracy of the measurement results. Work efficiency.

Benefits of technology

The simultaneous detection of three residual solvents in piperiquine phosphate is achieved, making up for the gap in quality control, improving the safety and detection accuracy of drugs, high sensitivity, and suitable for the quality control of drug raw materials.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115575544B_ABST
    Figure CN115575544B_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of drug detection, and provides a method for simultaneously determining the contents of three kinds of residual solvents in piperaquine phosphate. The method of the present invention adopts acidic (provided by sulfuric acid) ethylene glycol to completely dissolve the piperaquine phosphate to be tested, thereby ensuring the accuracy of the measurement result. Moreover, the present invention adopts the headspace sampling method, which effectively solves the problems of sample destruction, easy contamination of the liner, easy clogging of the injection needle, etc. caused by the direct sampling method, and greatly improves the work efficiency. The method provided by the present invention realizes the detection of residual solvents in piperaquine phosphate raw materials, makes up for the vacancy of the residual solvent test method in piperaquine phosphate, and has a positive effect on improving the safety of piperaquine phosphate. The embodiment shows that the method of the present invention has a good linear relationship within the concentration range of the investigation, the recovery rate meets the regulations, the sensitivity is high, the specificity is good, the result is accurate, and it can be used as a quality control method for residual solvents in piperaquine phosphate raw materials.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of drug detection, and in particular to a method for simultaneously determining the contents of three residual solvents in piperaquine phosphate. Background Art

[0002] Residual solvents in drugs refer to organic volatile compounds that are used in the production of raw materials, excipients and preparations but are not completely removed during the production process. In the synthesis process of raw materials, the selection of appropriate solvents can increase the yield or determine the properties of the drug, such as crystal form, purity and dissolution rate. Therefore, solvents are essential and very critical substances in drug synthesis reactions. When the level of residual solvents contained in drugs is higher than the safety value, it will cause harm to the human body or the environment, so the control of residual solvents has received more and more attention.

[0003] Piperaquine phosphate is one of the representative drugs for the treatment and control of malarial symptoms. It is used for the treatment of malaria and can also be used for symptom suppression prevention, especially for the treatment and prevention of malignant malaria caused by chloroquine-resistant strains. It can also be used to treat silicosis. It has a definite effect and has been used for decades. Its current quality standard is included in the second part of the 2015 edition of the Chinese Pharmacopoeia. There is no method for determining residual solvents in the quality standard, which makes its quality control lacking and cannot effectively control its quality. The synthesis of piperaquine phosphate is mainly obtained by two condensation reactions to obtain 1,3-bis[4-(7-chloro-quinoline-4-yl)piperazine-1-yl]propane, and then by the reaction of 1,3-bis[4-(7-chloro-quinoline-4-yl)piperazine-1-yl]propane with phosphoric acid. Guilin Nanyao Co., Ltd. has improved its synthesis route. According to the synthesis route, the solvents that may remain in the final product are methanol, ethanol and 1-bromo-3-chloropropane.

[0004] At present, there are literature reports on the determination of piperaquine phosphate content and related substances, but there are few reports on the determination of residual solvents in piperaquine phosphate raw materials. Pan Yong et al. (Pan Yong, Tang Qinghua, "Determination of ethanol solvent residues in piperaquine phosphate by liquid headspace gas chromatography", Life Science Instrument Research Brief, Volume 7 / April 2009, 49-50) reported a method for determining the residual amount of ethanol solvent in piperaquine phosphate, but the method disclosed in the document can only determine the content of residual solvent ethanol; the residual solvent 1-bromo-3-chloropropane and methanol were not determined. The residual solvent 1-bromo-3-chloropropane has potential genotoxic impurities, and its residual amount needs to be controlled; methanol has a great impact on the optic nerve, and can cause blindness in severe cases; if the 1-bromo-3-chloropropane and methanol residues in the drug are not subjected to limit inspection, there will be great safety hazards in the drug; and accurate control of drug quality cannot be achieved. Summary of the invention

[0005] In view of this, the object of the present invention is to provide a method for simultaneously determining the contents of three residual solvents in piperaquine phosphate. The determination method provided by the present invention can achieve simultaneous detection of three residual solvents, methanol, ethanol and 1-bromo-3-chloropropane, and realize quality control of piperaquine phosphate.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides a method for simultaneously determining the contents of three residual solvents in piperaquine phosphate, comprising the following steps:

[0008] Mix piperaquine phosphate to be tested, ethylene glycol and sulfuric acid to obtain a sample for testing;

[0009] After the sample is injected into the machine through headspace, it is subjected to gas chromatography detection to obtain a chromatogram of the sample;

[0010] The chromatogram of the sample on the machine is compared with the predetermined standard spectrum of the residual solvent, and the contents of the three residual solvents in the piperaquine phosphate to be tested are calculated by an external standard method;

[0011] The residual solvents include methanol, ethanol and 1-bromo-3-chloropropane;

[0012] The parameters of the headspace injection include: the equilibrium temperature of the headspace bottle is 80-90°C, and the equilibrium time is 25-35min;

[0013] The parameters of the gas chromatography detection include:

[0014] The chromatographic column is a DB-FFAP capillary column, a HP-FFAP capillary column or a PerkinElmer Elite-Wax;

[0015] The stationary liquid of the chromatographic column was polyethylene glycol;

[0016] The split ratio is 5:1 to 20:1;

[0017] The carrier gas is nitrogen;

[0018] The carrier gas flow rate is 5-7 mL / min;

[0019] The injection volume was 1 mL;

[0020] The heating program is:

[0021] Maintain at 35-55°C for 10 min; heat to 130°C at a rate of 50-70°C / min and maintain for 6 min; then heat to 220°C at a rate of 50-70°C / min and maintain for 5 min;

[0022] The injection port temperature is 200-240°C;

[0023] The detector temperature is 200-240°C.

[0024] Preferably, the usage ratio of the piperaquine phosphate to be tested, ethylene glycol and sulfuric acid is 0.15 g: 5 mL: 0.1 mL; and the mass concentration of the sulfuric acid is 95.0-98.0%.

[0025] Preferably, the mixing method includes ultrasound and shaking.

[0026] Preferably, the size of the chromatographic column is 60m×0.53mm×1.0μm, 30m×0.53mm×1.0μm, 30m×0.25mm×0.5μm or 30m×0.32mm×0.25μm.

[0027] Preferably, the predetermined residual solvent standard spectrum includes a predetermined methanol standard spectrum, a predetermined ethanol standard spectrum and a predetermined 1-bromo-3-chloropropane standard spectrum.

[0028] The invention provides a method for simultaneously determining the contents of three residual solvents in piperaquine phosphate, comprising the following steps: mixing piperaquine phosphate to be tested, ethylene glycol and sulfuric acid to obtain a sample on a machine; subjecting the sample on a machine to headspace sampling and then performing gas chromatography detection to obtain a chromatogram of the sample on a machine; comparing the chromatogram of the sample on a machine with a predetermined standard spectrum of residual solvents, and using an external standard method to calculate the contents of the three residual solvents in the piperaquine phosphate to be tested; the residual solvents include methanol, ethanol and 1-bromo-3-chloropropane; the parameters of the headspace sampling include: the equilibrium temperature of the headspace bottle is 80-90°C, and the equilibrium time is 25-35min; the parameters of the gas chromatography detection include: the chromatographic column is a DB-FFAP capillary column, an HP-FFAP capillary column or a PerkinElmer Elite-Wax; the stationary liquid of the chromatographic column is polyethylene glycol; the split ratio is 5:1-20:1; the carrier gas is nitrogen; the carrier gas flow rate is 5-7mL / min; the injection volume is 1mL; the heating program is: maintain at 35-55℃ for 10min; increase the temperature to 130℃ at a rate of 50-70℃ / min, maintain for 6min; then increase the temperature to 220℃ at a rate of 50-70℃ / min, maintain for 5min; the injection port temperature is 200-240℃; the detector temperature is 200-240℃.

[0029] The method of the present invention adopts acidic (provided by sulfuric acid) ethylene glycol to completely dissolve the piperaquine phosphate to be tested, thereby ensuring the accuracy of the measurement result. Moreover, the present invention adopts the headspace sampling method, which effectively solves the problems of sample destruction, contamination of the liner, and clogging of the injection needle caused by the direct sampling method, and greatly improves the working efficiency. The method provided by the present invention realizes the simultaneous detection of three residual solvents (methanol, ethanol and 1-bromo-3-chloropropane) in piperaquine phosphate, makes up for the vacancy of the residual solvent test method in piperaquine phosphate, and has a positive effect on improving the safety of piperaquine phosphate. The data of the embodiment show that the method of the present invention has a good linear relationship within the concentration range of the investigation, the recovery rate meets the regulations, the sensitivity is high, the specificity is good, the result is accurate, and it can be used as a quality control method for residual solvents in piperaquine phosphate raw materials. At the same time, the limit of the method of the present invention to 1-bromo-3-chloropropane is 0.002%, indicating that the method provided by the present invention is very sensitive. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 is the chromatogram of blank solvent (ethylene glycol);

[0031] Figure 2 is the chromatogram of the mixed reference solution;

[0032] Figure 3 for Figure 2 A partial enlarged view of

[0033] Figure 4 The chromatogram is of the test solution (sample batch number is PP150102) in Example 1;

[0034] Figure 2 to Figure 4 In the above formula, 1 is methanol, 2 is ethanol, and 3 is 1-bromo-3-chloromethane. DETAILED DESCRIPTION

[0035] The present invention provides a method for simultaneously determining the contents of three residual solvents in piperaquine phosphate, comprising the following steps:

[0036] Mix piperaquine phosphate to be tested, ethylene glycol and sulfuric acid to obtain a sample for testing;

[0037] The sample on the machine is subjected to headspace sampling and then subjected to gas chromatography detection to obtain a chromatogram of the sample on the machine;

[0038] The chromatogram of the sample on the machine is compared with the predetermined standard spectrum of the residual solvent, and the contents of the three residual solvents in the piperaquine phosphate to be tested are calculated by an external standard method;

[0039] The residual solvents include methanol, ethanol and 1-bromo-3-chloropropane;

[0040] The parameters of the headspace injection include: the equilibrium temperature of the headspace bottle is 80-90°C, and the equilibrium time is 25-35min;

[0041] The parameters of the gas chromatography detection include:

[0042] The chromatographic column is a DB-FFAP capillary column, a HP-FFAP capillary column or a PerkinElmer Elite-Wax;

[0043] The stationary liquid of the chromatographic column was polyethylene glycol;

[0044] The split ratio is 5:1 to 20:1;

[0045] The carrier gas is nitrogen;

[0046] The carrier gas flow rate is 5-7 mL / min;

[0047] The injection volume was 1 mL;

[0048] The heating program is:

[0049] Maintain at 35-55°C for 10 min; heat to 130°C at a rate of 50-70°C / min and maintain for 6 min; then heat to 220°C at a rate of 50-70°C / min and maintain for 5 min;

[0050] The injection port temperature is 200-240°C;

[0051] The detector temperature is 200-240°C.

[0052] In the present invention, unless otherwise specified, the raw materials used in the present invention are preferably commercially available products.

[0053] The present invention mixes piperaquine phosphate to be tested, ethylene glycol and sulfuric acid to obtain a sample for use on a machine. In the present invention, the dosage ratio of the piperaquine phosphate to be tested, ethylene glycol and sulfuric acid is preferably 0.15 g: 5 mL: 0.1 mL; the mass concentration of the sulfuric acid is preferably 95.0-98.0%. In the present invention, the mixing method preferably includes ultrasound and shaking; the present invention does not specifically limit the parameters of the ultrasound and shaking, as long as the piperaquine phosphate to be tested can be completely dissolved.

[0054] After obtaining the sample on the machine, the present invention performs headspace sampling on the sample on the machine and then performs gas chromatography detection to obtain a chromatogram of the sample on the machine.

[0055] In the present invention, the parameters of the head space injection include: the equilibrium temperature of the head space bottle is 80-90° C., preferably 85° C.; the equilibrium time is 25-35 min, preferably 30 min.

[0056] In the present invention, the parameters detected by gas chromatography include:

[0057] The chromatographic column is a DB-FFAP capillary column, a HP-FFAP capillary column or a PerkinElmer Elite-Wax, preferably a DB-FFAP capillary column; the size of the chromatographic column is preferably 60m×0.53mm×1.0μm, 30m×0.53mm×1.0μm, 30m×0.25mm×0.5μm or 30m×0.32mm×0.25μm, more preferably 60m×0.53mm×1.0μm;

[0058] The stationary liquid of the chromatographic column was polyethylene glycol;

[0059] The split ratio is 5:1 to 20:1, preferably 10:1;

[0060] The carrier gas is nitrogen;

[0061] The carrier gas flow rate is 5-7 mL / min, preferably 5 mL / min;

[0062] The injection volume was 1 mL;

[0063] The heating program is:

[0064] Maintain at 35-55°C for 10 min; heat to 130°C at a rate of 50-70°C / min, maintain for 6 min; then heat to 220°C at a rate of 50-70°C / min, maintain for 5 min; preferably: maintain at 45°C for 10 min; heat to 130°C at a rate of 60°C / min, maintain for 6 min; then heat to 220°C at a rate of 60°C / min, maintain for 5 min;

[0065] The injection port temperature is 200-240°C, preferably 220°C;

[0066] The detector temperature is 200-240°C, preferably 220°C.

[0067] In the present invention, the gas chromatography detection parameters can make the theoretical plate number calculated based on the methanol peak not less than 5000, and the separation degree between the peaks of each component meets the requirements.

[0068] After obtaining the chromatogram of the sample on the machine, the present invention compares the chromatogram of the sample on the machine with a predetermined standard spectrum of the residual solvent, and uses an external standard method to calculate the contents of the three residual solvents in the piperaquine phosphate to be tested.

[0069] In the present invention, the method for obtaining the predetermined standard spectrum of the residual solvent preferably comprises the following steps:

[0070] Provide reference solution;

[0071] The reference solution is sampled by headspace injection and then subjected to gas chromatography detection to obtain a predetermined standard spectrum of the residual solvent.

[0072] In the present invention, the reference solution preferably includes methanol, ethanol and 1-bromo-3-chloropropane; the solvent of the reference solution is preferably ethylene glycol; the reference solution preferably includes sulfuric acid; the concentration and dosage of the sulfuric acid are preferably consistent with the above technical solution, which will not be repeated here. In the present invention, the parameters of the headspace injection and gas chromatography detection are preferably consistent with the above technical solution, which will not be repeated here.

[0073] The method for simultaneously determining the contents of three residual solvents in piperaquine phosphate provided by the present invention is described in detail below in conjunction with the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0074] Example 1

[0075] 1. Solution preparation and testing

[0076] 1.1 Solution preparation

[0077] (1) Preparation of test solution: Take 0.15 g of piperaquine phosphate from three batches (sample 1, sample 2 and sample 3), accurately weigh, place in a 20-mL headspace bottle, accurately add 5 mL of ethylene glycol and 0.1 mL of sulfuric acid (mass concentration of 95.0-98.0%), cover and seal, and shake by ultrasonication to dissolve the piperaquine phosphate. Shake well to prepare the test solution.

[0078] (2) Preparation of reference substance solution: Weigh 0.45 g methanol, 0.75 g ethanol, and 0.09 g 1-bromo-3-chloropropane, accurately weigh, place in the same 50 mL volumetric flask, shake to dissolve 1-bromo-3-chloropropane in methanol and ethanol, dilute to scale with ethylene glycol, shake well, and use as mixed reference substance stock solution; accurately measure 1 mL of mixed reference substance stock solution, place in a 100 mL volumetric flask, dilute to scale with ethylene glycol, shake well, and use as mixed reference substance dilution solution; accurately measure 5 mL of mixed reference substance dilution solution, place in a 20 mL headspace bottle, accurately add 0.1 mL of sulfuric acid (mass concentration is 95.0-98.0%), cover and seal, shake well, and use as mixed reference substance solution.

[0079] Figure 1 is the chromatogram of blank solvent (ethylene glycol), Figure 2 is the chromatogram of the mixed reference solution. Figure 3 for Figure 2 A partial enlarged view of Figure 4 The chromatogram is of the test solution (sample batch number is PP150102) in Example 1; Figure 2 to Figure 4 In the formula, 1 is methanol, 2 is ethanol, and 3 is 1-bromo-3-chloromethane. Figures 1 to 4It can be seen that the blank solvent has no interference with the determination of methanol, ethanol and 1-bromo-3-chloromethane; the separation degree between each substance can reach baseline separation.

[0080] 1.2 Detection parameters:

[0081] Headspace injection parameters: headspace bottle equilibrium temperature is 85°C, equilibrium time is 30 min;

[0082] Gas chromatography detection parameters: the chromatographic column is an Agilent DB-FFAP capillary column, 60m×0.53mm×1.0μm, with polyethylene glycol (PEG-20M) as the stationary liquid; the split ratio is 10:1; the heating program is as follows: the column temperature is maintained at 45°C for 10 min, increased to 130°C at a rate of 60°C / min, maintained for 6 min, and then increased to 220°C at a rate of 60°C / min, maintained for 5 min; the injection port temperature is 220°C; the detector temperature is 220°C; the carrier gas is nitrogen, flow rate: 5mL / min; injection volume: 1mL.

[0083] Take the reference solution for headspace injection. The theoretical plate number calculated based on the methanol peak should not be less than 5000, and the separation between the peaks of each component should meet the requirements.

[0084] 1.3 Determination and calculation

[0085] Take the reference solution and the test solution for headspace injection and gas chromatography detection according to the parameters in the detection parameters section, and record the chromatograms; calculate by peak area using the external standard method, the residual amounts of methanol, ethanol, and 1-bromo-3-chloropropane should not exceed 0.3%, 0.5%, and 0.002%, respectively.

[0086] 2 Methodological validation

[0087] 2.1. Linear relationship investigation

[0088] A series of concentration solutions of methanol, ethanol and 1-bromo-3-chloropropane were prepared. The linear relationship results of methanol, ethanol and 1-bromo-3-chloropropane are shown in Table 1.

[0089] Table 1 Regression equation and linear relationship

[0090]

[0091] It can be seen from Table 1 that methanol, ethanol and 1-bromo-3-chloropropane have a good linear relationship with the peak area within the corresponding concentration range.

[0092] 2.2. Precision test

[0093] Six portions of the reference solution were measured in parallel, and the RSDs of the peak areas of methanol, ethanol, and 1-bromo-3-chloropropane were calculated, which were 3.60%, 2.28%, and 1.18% (n=6), respectively, indicating that the chromatographic system had good precision.

[0094] 2.3. Repeatability test

[0095] Since the residual solvent content of this product is low, the 100% recovery solution under the recovery item is used as the evaluation of the repeatability test. The RSDs of methanol, ethanol, and 1-bromo-3-chloromethane are 0.91%, 0.98%, and 2.18% (n=6), respectively, indicating good repeatability.

[0096] 2.4 Limit of detection and limit of quantification

[0097] The reference solution was diluted step by step and the detection limit was determined by S / N≈3 and the quantification limit was determined by S / N≈10. The detection limits of methanol, ethanol and 1-bromo-3-chloropropane were 0.088, 0.13 and 0.068 μg·mL, respectively. -1 The limits of quantification were 0.31, 0.39, and 0.23 μg·mL -1 .

[0098] 2.5 Determination of recovery rate

[0099] The average recovery rate and RSD value of each component were determined and calculated. The results are shown in Table 2.

[0100] Table 2 Residual solvent recovery test results in piperaquine phosphate (n=9)

[0101]

[0102]

[0103] It can be seen from Table 2 that the method provided by the present invention has a good recovery rate.

[0104] 2.6 Durability test

[0105] Take the reference solution and change the carrier gas flow rate to (6.0±1.0) mL·min -1, injection port temperature (220±20)℃, split ratio (5:1, 20:1), initial temperature of the heating program (45±10)℃, heating rate (60±10)℃ / min, detector temperature (220±20)℃; headspace equilibration time (30±5)min, heating temperature (85±5)℃; different chromatographic columns (Agilent HP-FFAP (30m×0.53mm×1.0μm), Agilent DB-WAXETR (30m×0.25mm×0.5μm), PerkinElmerElite-Wax (30m×0.32mm×0.25μm) for headspace injection, the system suitability under the experimental conditions was investigated. Results The system suitability parameters under each experimental condition met the requirements, indicating that the method has good durability.

[0106] 2.7 Establishment of limits for 1-bromo-3-chloropropane

[0107] 1-Bromo-3-chloropropane has potential genotoxicity. There is no literature report on the safety risk assessment of its genotoxicity, and the literature report has not determined its limit. The present invention determines its limit for the first time: the limit is formulated according to the ICH M7 guideline: piperaquine phosphate is calculated according to the longest-used prevention and treatment of silicosis, with a therapeutic dose of 0.5g to 0.75g / time, once a week, 2g per month, and half a year as a course of treatment; after a one-month break, the second course of treatment can be carried out. That is to say, a cycle of 7 months, and the number of days for taking a cycle is 24 days, so according to the most conservative 70 years, the total treatment period = 70×12 / 7×24 = 2880 days = 7.9 years. Therefore, according to Table 2 of ICH M7, the daily dose of 1-Bromo-3-chloropropane is 0.5g, and the PDE is 10μg / day. Therefore, the limit of 1-bromo-3-chloropropane = PDE / daily dose = (10 μg / day) / (0.5 g / day) = 20 ppm, i.e. 0.002%. The method of the present invention can accurately measure at such a low limit (0.002%), indicating that the method of the present invention is very sensitive.

[0108] 2.8 Selection of sample dissolving solvent

[0109] According to relevant guidelines, the solvent used to determine the residual solvent sample should be able to completely dissolve the sample. The methods for determining the residual solvent of piperaquine phosphate reported in the existing literature have not been able to completely dissolve piperaquine phosphate. The present invention has conducted a large number of experiments and tried to use carbon disulfide, xylene, carbon tetrachloride, n-heptane, toluene, acetonitrile, chloroform, n-hexane, dimethyl sulfoxide, and N,N-dimethylformamide to dissolve the sample. The results showed that the samples could not be completely dissolved.

[0110] The test showed that the mixture of ethylene glycol and sulfuric acid can effectively dissolve the sample, ensuring that the residual organic solvent in the piperaquine phosphate to be tested can be completely dissolved, thus ensuring the accuracy of the test results.

[0111] 2.9 Selection of injection method

[0112] At present, the main methods for determining residual solvents are direct injection and head space injection. The methods for determining residual solvents of piperaquine phosphate reported in the literature are generally direct injection. The present invention uses the head space injection method, which effectively solves the problems of sample destruction, easy contamination of the liner, easy clogging of the injection needle, etc. caused by the direct injection method, and greatly improves the work efficiency.

[0113] 3. Sample determination

[0114] Take appropriate amount of reference solution and test solution, measure according to the detection parameters in 1.2, and calculate according to the external standard method. The results are shown in Table 3.

[0115] Table 3 Determination results of residual solvents in piperaquine phosphate (n=2)

[0116]

[0117] As can be seen from Table 3: the test results of the three batches of piperaquine phosphate samples all meet the requirements (methanol limit 0.3%, ethanol limit 0.5%, and 1-bromo-3-chloropropane proposed limit 0.002%).

[0118] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for simultaneously determining the contents of three residual solvents in piperaquine phosphate, characterized in that: The following steps are involved: Mix piperaquine phosphate to be tested, ethylene glycol and sulfuric acid to obtain a sample for testing; After the sample is injected into the machine through headspace, it is subjected to gas chromatography detection to obtain a chromatogram of the sample; The chromatogram of the sample on the machine is compared with the predetermined standard spectrum of the residual solvent, and the contents of the three residual solvents in the piperaquine phosphate to be tested are calculated by an external standard method; The residual solvents include methanol, ethanol and 1-bromo-3-chloropropane; The parameters of the headspace injection include: the equilibrium temperature of the headspace bottle is 80-90°C, and the equilibrium time is 25-35min; The parameters of the gas chromatography detection include: The chromatographic column is a DB-FFAP capillary column, a HP-FFAP capillary column or a PerkinElmer Elite-Wax; The stationary liquid of the chromatographic column was polyethylene glycol; The split ratio is 5:1 to 20:1; The carrier gas is nitrogen; The carrier gas flow rate is 5-7 mL / min; The injection volume was 1 mL; The heating program is: Maintain at 35-55°C for 10 min; heat to 130°C at a rate of 50-70°C / min and maintain for 6 min; then heat to 220°C at a rate of 50-70°C / min and maintain for 5 min; The injection port temperature is 200-240°C; The detector temperature is 200-240°C; The dosage ratio of the piperaquine phosphate to be tested, ethylene glycol and sulfuric acid is 0.15 g: 5 mL: 0.1 mL; the mass concentration of the sulfuric acid is 95.0-98.0%.

2. The simultaneous determination method according to claim 1, characterized in that: The mixing methods include ultrasound and shaking.

3. The simultaneous determination method according to claim 1, characterized in that: The size of the chromatographic column is 60m×0.53mm×1.0μm, 30m×0.53mm×1.0μm, 30m×0.25mm×0.5μm or 30m×0.32mm×0.25μm.

Citation Information

Patent Citations

  • Bosutinib purification method

    CN110317168A

  • Crystalline and amorphous form of aclidinium chloride and method for their preparation

    WO2015144101A1